Single-use Bioreactors Market Size & Growth Forecast 2026–2035, By Segments (Usage Type, End-use, Product Scope, Type, Molecule Type, Application, Type of Cell), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Single-use Bioreactors Market size was worth USD 4.99 Billion in 2025 and is poised to grow at a 17% CAGR between 2026 and 2035, reaching USD 23.99 Billion by 2035. The industry revenue for 2026 is assessed at USD 5.75 billion.

• Base Year Value (2025): USD 4.99 Billion
• CAGR (2026-2035): 17%
• Forecast Year Value (2035): USD 23.99 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Single-use Bioreactors Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 36.29% share in 2025, driven by its strong biopharmaceutical manufacturing base, mature outsourcing ecosystem, and widespread adoption of flexible biologics production systems.
  • Asia Pacific is projected to expand at a 19.04% CAGR as biologics manufacturing capacity grows and facilities increasingly adopt disposable systems for faster setup, scalability, and cost-efficient production.

• Segment Momentum:

  • Lab-scale Production held a 37.76% share in 2025 because it supports early-stage research, pilot studies, and rapid process development through flexible systems with reduced cleaning and changeover requirements.
  • Pharmaceutical & Biopharmaceutical Companies are the fastest-growing end users as they expand flexible manufacturing capacity to accelerate development timelines and improve adaptability across multiple biologic production programs.

• Market Expansion Drivers:

  • Flexibility and contamination reduction accelerating biopharmaceutical production adoption.
  • Lower operational costs and faster turnaround versus stainless steel systems.
  • Expanding biologics pipeline and scaling of CMO/CDMO manufacturing capacity.

• Leading Market Participants:

  Major companies in the single-use bioreactors market include Sartorius AG (Germany), Thermo Fisher Scientific Inc. (United States), Merck KGaA (Germany), Danaher Corporation (United States), Lonza Group AG (Switzerland), Getinge AB (Sweden), Eppendorf SE (Germany), PBS Biotech, Inc. (United States), Celltainer Biotech B.V. (Netherlands), Cellexus International Ltd. (United Kingdom).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 4.99 Billion
  • Projected Market Size: USD 23.99 Billion by 2035
  • Growth Forecasts: 17% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Lab-scale Production (Usage Type) | CROs & CMOs (End-use) | Single-use Bioreactor Systems (Product Scope) | Stirred-tank SUBs (Type) | Vaccines (Molecule Type) | Bioproduction (Application) | Mammalian Cells (Type of Cell)
  • Emerging Opportunity Segment: Large-scale Production (Usage Type) | Pharmaceutical & Biopharmaceutical Companies (End-use) | Single-use Bioreactor Systems (Product Scope) | Stirred-tank SUBs (Type) | Gene Modified Cells (Molecule Type) | Bioproduction (Application) | Mammalian Cells (Type of Cell)

Market Growth Drivers and Industry Trends

Flexibility and contamination reduction accelerating biopharmaceutical production adoption

Biopharmaceutical manufacturers increasingly favor modular production setups that can be deployed quickly, reconfigured between products, and operated with lower cross-batch contamination risk, which is increasing demand for the single-use bioreactors market. Single-use systems remove much of the cleaning validation and sterilization burden associated with fixed stainless steel infrastructure, making them especially attractive for facilities handling multiple biologics, clinical-stage programs, or smaller commercial batches. In practice, this flexibility supports faster product changeovers and shortens facility readiness timelines, while the reduced contamination exposure strengthens confidence in batch integrity and reinforces market adoption among firms prioritizing speed, product segregation, and manufacturing reliability.

Lower operational costs and faster turnaround versus stainless steel systems

Cost discipline and production agility are closely linked in bioprocessing decisions, and both are aiding market expansion for the single-use bioreactors market as manufacturers seek alternatives to capital-intensive stainless steel systems. Disposable bioreactor formats reduce spending tied to cleaning utilities, steam generation, water-for-injection consumption, and maintenance of permanent vessels, while also limiting downtime between batches. That operating model influences procurement and capacity planning in practice: companies can bring lines online faster, improve asset utilization, and respond more efficiently to fluctuating production schedules, which is increasing market adoption among both established biologics producers and emerging biotech firms.

Expanding biologics pipeline and scaling of CMO/CDMO manufacturing capacity

A broader biologics development pipeline is translating into more outsourced manufacturing activity, and that dynamic is strengthening market development for the single-use bioreactors market. CMOs and CDMOs need equipment platforms that can support diverse molecules, variable batch sizes, and overlapping client timelines without locking capacity into inflexible fixed systems. Single-use bioreactors fit this model by enabling rapid suite turnover and easier scale-up from process development to commercial production, which aligns with how outsourced manufacturers build capacity around responsiveness and multi-client utilization. As biologics sponsors rely more heavily on external partners to advance programs and expand output, investment in disposable bioprocessing infrastructure is contributing to market size growth.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Flexibility and contamination reduction accelerating biopharmaceutical production adoption	2.50%	High	North America, Europe, Asia Pacific	High	Near Term
Lower operational costs and faster turnaround versus stainless steel systems	2.10%	High	North America, Europe	High	Near Term
Expanding biologics pipeline and scaling of CMO/CDMO manufacturing capacity	1.90%	High	North America, Asia Pacific, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 36.29% share of the single-use bioreactors market in 2025, bolstered by the region’s established biopharmaceutical manufacturing base and broad use of flexible production systems across commercial and clinical-scale operations. Demand remains concentrated in settings where manufacturers need faster batch changeovers, lower cleaning validation burdens, and scalable capacity for biologics production, all of which favor single-use deployment. The region’s position is further strengthened by the presence of major industry participants, mature outsourcing networks, and sustained investment in process optimization, which keeps adoption embedded in everyday manufacturing decisions.

Asia Pacific is projected to expand at a 19.04% CAGR over the forecast period, with the single-use bioreactors market gaining momentum as biopharmaceutical capacity builds out across both domestic production and contract manufacturing environments. Growth is being impelled by increasing installation of modern biologics facilities that prefer disposable systems for quicker setup, lower upfront infrastructure requirements, and easier adaptation to changing production volumes. As manufacturers in the region scale development and manufacturing capabilities, adoption is accelerating in practical use cases where speed, flexibility, and cost control are central to facility planning.

Key Country Insights

United States

Bioprocess Expansion Center

The U.S. continues investing in flexible biomanufacturing capacity where single-use bioreactors support rapid process development and commercial production. Companies across the U.S. prioritize scalable manufacturing platforms, automation, and contamination risk reduction for biologics production.

Japan

Quality-Focused Bioprocessing

Japan adopts single-use bioreactors to improve manufacturing flexibility while maintaining stringent quality standards for biologics production. Organizations in Japan emphasize reliable process control, regulatory compliance, and consistent product quality across development and manufacturing stages.

South Korea

Biologics Capacity Development

South Korea continues strengthening biopharmaceutical manufacturing through broader adoption of single-use bioreactor technologies. Companies in South Korea invest in modern production facilities capable of supporting contract manufacturing, process efficiency, and rapid product transitions.

Germany

Advanced Manufacturing Integration

Germany integrates single-use bioreactors into highly automated biopharmaceutical production environments. Manufacturers in Germany focus on efficient process validation, equipment compatibility, and sustainable production practices while supporting diverse biologics manufacturing requirements.

France

Flexible Production Strategy

France incorporates single-use bioreactors to support clinical manufacturing and specialized biologics production with greater operational flexibility. Organizations in France prioritize efficient facility utilization, faster changeovers, and reliable production processes for innovative therapies.

Italy

Specialized Biomanufacturing Support

Italy applies single-use bioreactors across research organizations and pharmaceutical manufacturers seeking adaptable production capabilities. Companies in Italy emphasize cost-efficient scale-up, process consistency, and technology upgrades that support expanding biologics development activities.

Segment Leadership and Growth Trends

  Usage Type Segment Analysis: Lab-scale Production (Largest Segment) vs Large-scale Production (Fastest-Growing Segment)

Lab-scale Production held the leading position in the single-use bioreactors market in 2025, accounting for a 37.76% share. Its leadership is underpinned by the high volume of early-stage research, process development, and pilot experimentation that relies on flexible bioreactor setups with lower changeover burden. In the single-use bioreactors market, lab-scale systems fit well with rapid testing cycles and small-batch workflows, making them a practical choice for organizations that need speed, containment efficiency, and reduced cleaning requirements during development activities.

Large-scale Production is the fastest-growing segment in the single-use bioreactors market as manufacturers increasingly extend disposable technologies into commercial and late-stage production environments. Growth is being backed by the need to expand output without the long installation timelines and operational rigidity associated with traditional stainless-steel systems. Compared with smaller-scale use cases, large-scale production is gaining momentum because it directly addresses evolving manufacturing requirements for scalable capacity, faster facility readiness, and more adaptable batch production.

End-use Segment Analysis: CROs & CMOs (Largest Segment) vs Pharmaceutical & Biopharmaceutical Companies (Fastest-Growing Segment)

In 2025, CROs & CMOs represented the largest end-use segment in the single-use bioreactors market, with a 40.97% share. Their leadership reflects the outsourced manufacturing model increasingly used across bioprocessing, where clients depend on external partners for development and production flexibility. The single-use bioreactors market benefits from this model because CROs and CMOs must manage varied client programs, smaller batch runs, and frequent product changeovers, all of which align well with disposable bioreactor platforms.

Pharmaceutical & Biopharmaceutical Companies are emerging as the fastest-growing end-use segment in the single-use bioreactors market due to rising internal adoption of flexible manufacturing infrastructure. Growth is being driven by the need to shorten development-to-production timelines while maintaining operational adaptability across different biologic programs. Relative to outsourced settings, direct adoption by pharmaceutical and biopharmaceutical companies is gaining pace as these firms increasingly build or upgrade facilities around single-use systems to support faster process transitions and more responsive production planning.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Usage Type	Lab-scale Production, Pilot-scale Production, Large-scale Production	Lab-scale Production	Large-scale Production
End-use	Pharmaceutical & Biopharmaceutical Companies, CROs & CMOs, Academic & Research Institutes	CROs & CMOs	Pharmaceutical & Biopharmaceutical Companies
Product Scope	Single-use Bioreactor Systems, Single-use Media Bags, Single-use Filtration Assemblies, Others	Single-use Bioreactor Systems	Single-use Bioreactor Systems
Type	Stirred-tank SUBs, Wave-induced SUBs, Bubble-column SUBs, Others	Stirred-tank SUBs	Stirred-tank SUBs
Molecule Type	Monoclonal Antibodies, Vaccines, Gene Modified Cells, Stem Cells, Others	Vaccines	Gene Modified Cells
Application	Research and Development (R&D)or Process Development, Bioproduction	Bioproduction	Bioproduction
Type of Cell	Mammalian Cells, Bacterial Cells, Yeast Cells, Others	Mammalian Cells	Mammalian Cells

Competitive Landscape and Market Positioning

Top players in the single-use bioreactors market:

1. Sartorius AG (Germany)

2. Thermo Fisher Scientific Inc. (United States)

3. Merck KGaA (Germany)

4. Danaher Corporation (United States)

5. Lonza Group AG (Switzerland)

6. Getinge AB (Sweden)

7. Eppendorf SE (Germany)

8. PBS Biotech Inc. (United States)

9. Celltainer Biotech B.V. (Netherlands)

10. Cellexus International Ltd. (United Kingdom)

The single-use bioreactors market is growing rapidly due to increasing demand for flexible biomanufacturing solutions. In the single-use bioreactors market, advancements in disposable system design are improving production scalability. Enhanced process control technologies are also supporting biopharmaceutical innovation.

Industry Development/News

Company Name	Date	Key Development
AGC Biologics	Apr-25	AGC Biologics integrated two 5,000L Thermo Scientific DynaDrive single-use bioreactors into its Yokohama facility. This investment enhances the site's capability for large-scale mammalian-based biologic production, establishing a sophisticated infrastructure in Japan to meet the growing demand for flexible, high-capacity CDMO manufacturing services.
WuXi Biologics	Apr-25	WuXi Biologics successfully completed the first commercial Process Performance Qualification (PPQ) campaign at its MFG20 facility in Hangzhou. The project utilized a second drug substance line equipped with three 5,000L single-use bioreactors, validating the facility's readiness for large-scale commercial biologics manufacturing and operational scalability.
Fujifilm Biotechnologies	Nov-24	Fujifilm Biotechnologies completed a £400 million expansion of its Teesside facility, adding 19,000L of single-use bioreactor capacity alongside a new innovation center. This investment significantly bolsters the company’s global CDMO antibody production capabilities and process development infrastructure to support increasing biopharmaceutical manufacturing volume requirements.
Bora Group	Nov-24	Bora Group acquired MacroGenics’ CDMO operations for up to $127.5 million, securing a Maryland-based drug-substance facility. The acquisition integrates advanced single-use bioprocessing capabilities into Bora’s biologics platform, expanding its total capacity for late-stage development and commercial-scale manufacturing of complex biologic drug products.
WuXi Biologics	Oct-24	WuXi Biologics expanded its manufacturing footprint by installing three 5,000L single-use bioreactors, effectively increasing total site capacity from 8,000L to 23,000L. This capacity upgrade enhances GMP production throughput and cost-efficiency, reinforcing the industry-wide shift toward large-scale single-use technologies for commercial antibody manufacturing operations.
Syngene	Oct-24	Syngene initiated an expansion of its biomanufacturing infrastructure in India, with a new facility projected to triple its current production capacity. The investment enhances the company’s CDMO service offerings, specifically targeting the demand for large-scale, single-use bioreactor-based production processes for pharmaceutical and biopharmaceutical clients.
Thermo Fisher Scientific	Oct-24	Thermo Fisher Scientific partnered with the Telangana government to establish a 10,000 sq. ft. Bioprocess Design Center in India, with operations commencing in 2025. The center will focus on advancing biotherapeutic development workflows, specifically enhancing technical capabilities in single-use bioreactor design and regional bioprocessing innovation.
MicroDigital	Oct-24	MicroDigital launched a new line of single-use bioreactors in the United States, officially entering the commercial bioprocessing equipment supply market. The technology provides manufacturers with flexible, scalable solutions for biologics production, reflecting the increasing availability and adoption of disposable bioprocessing systems in the North American pharmaceutical sector.
Biosphere	Oct-24	Biosphere secured $8.8 million in seed funding to advance its UV-sterilized, single-use bioreactor platform. The investment is targeted at scaling technology designed to lower biomanufacturing costs and improve process efficiency, representing a strategic effort to introduce novel sterilization methods into standard single-use production workflows.
Aragen	Dec-24	Aragen demonstrated accelerated commercial GMP scale-up capabilities by transferring a monoclonal antibody program from California to Bengaluru in nine months. The successful execution utilized single-use bioreactor production workflows, highlighting the company’s improved tech transfer speed and CDMO execution proficiency for high-risk therapeutic manufacturing.